Antipsychotic drugs and reproductive hormones relationship to body weight regulation

Pharmacology Biochemistry and Behavior

Volumn 62, Issue 3, 1999, Pages 409-417

  Baptista, Trino ^a   Reyes, Dorys ^a   Hernández, Luis ^a  

^a UNIVERSIDAD DE LOS ANDES   (Venezuela)

Author keywords

Antipsychotics; Neuroleptics; Obesity; Reproductive hormones

Indexed keywords

CHLORPROMAZINE; ESTRADIOL; FLUPHENAZINE; FOLLITROPIN; HALOPERIDOL; HYDROCORTISONE; LEVOMEPROMAZINE; LIOTHYRONINE; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; PLACEBO; PRASTERONE SULFATE; PROGESTERONE; PROLACTIN; SULPIRIDE; TESTOSTERONE; THIORIDAZINE; THYROTROPIN; THYROXINE; TRIFLUOPERAZINE;

ADULT; AFFECTIVE NEUROSIS; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYPERPROLACTINEMIA; MALE; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; ANDROGENS; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; BODY WEIGHT; DEHYDROEPIANDROSTERONE SULFATE; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; GONADAL STEROID HORMONES; HUMANS; LUTEINIZING HORMONE; MALE; PROGESTERONE; SCHIZOPHRENIA; THYROID HORMONES;

EID: 0032979692     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(98)00188-9     Document Type: Article

References (75)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. 4:1994;American Psychiatric Association, Washington, DC.
2. Aso T., Matsouka M., Su J., Horie K., Taii S., Motohashi T., Nishimura T. Influence of sulpiride-induced hyperprolactinemia on baboon menstrual cycles. A longitudinal study J. Med. Primatol. 11:1982;20-34.
3. Ataya K., Mercado A., Kartaginer J., Abbasi J., Moghissi K.S. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil. Steril. 50:1988;876-881.
4. 2 dopamine receptors involved? Pharmacol. Biochem. Behav. 27:1987;399-405.
5. Baptista T., Hernández L., Hoebel B.G. Systemic sulpiride increases dopamine metabolites in the lateral hypothalamus. Pharmacol. Biochem. Behav. 37:1990;227-229.
6. Baptista T., Uzcategui E. Substance use among resident doctors in Venezuela. Drug Alcohol. Depend. 32:1992;127-132.
7. Baptista T., Teneud L., Contreras Q., Alastre T., Burguera J.L., de Burguera M., de Baptista E., Weiss S.R.B., Hernandez L. Lithium and body weight gain. Pharmacopsychiatry. 28:1995;35-44.
8. Baptista T., López M.A., Teneud L., Contreras Q., Alastre T., Quijada M., Weiss S.R.B., Altemus M., Páez X., Hernández L. Amantadine in the treatment of neuroleptic-induced obesity in rats. Pharmacopsychiatry. 30:1997;1-12.
9. Baptista T., de Baptista E., Altemus M., Weiss S.R.B., Hernández L. Tamoxifen prevents sulpiride-induced obesity in female rats. Pharmacol. Biochem. Behav. 57:1997;215-222.
10. Baptista T., Calanche I., Quijada M., Contreras Q., Martinez J.L., Martinez J.M., Hernandez L. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women. Relationship with body weight regulation Pharmacopsychiatry. 30:1997;256-262.
11. Baptista T., Contreras Q., Teneud L., Albornoz M.A., Acosta A., Páez X., Quijada M., LaCruz A., Hernández L. Mechanism of the neuroleptic-induced obesity in female rats. Prog. Neuropsychopharmacol. Biol. Psychiatry. 22:1998;187-198.
12. Bech P., Kastrup M., Rafaelsen O.J. Mini-compendium of rating scales of anxiety, depression, mania and schizophrenia, with corresponding DSM-III syndromes. Acta Psychiatr. Scand. Suppl. 326:1986;7-36.
13. Bernstein J.G. Management of psychotropic drug-induced obesity. Björntrop P., Brodoff B.N. Obesity. 1992;Lippincott Company, Philadelphia.
14. Besser G.M., Thorner M.O. Prolactin and gonadal function. Pathol. Biol. (Paris). 23:1975;779-782.
15. Beumont P.J.V., Gelder M.G., Friesen H.G., Harris G.W., Mackinnon P.C.B., Mandelbrote B.M., Wiles D.H. The effects of phenothiazines on endocrine function. I. Patients with inappropiate lactation and amenorrhoea. Br. J. Psychiatry. 124:1974;413-419.
16. Beumont P.J.V., Corker C.S., Friesen H.G., Kakowska T., Mandelbrote B.M., Marshall J., Murray M.A.F., Wiles D.H. Effects of phenothiazines on endocrine function. II. Effects in men and post-menopausal women. Br. J. Psychiatry. 124:1974;420-430.
17. Bhavnani S.M., Levin G.M. Antipsychotic agents. A survey of the prevalence, severity and burden of side effects Int. Clin. Psychopharmacol. 11:1996;1-12.
18. Björntorp P. Endocrine abnormalities of obesity. Metabolism (Suppl.). 44:1995;21-23.
19. Borison R.L., Pathiraja A.P., Diamond B.I., Meibach R.C. Risperidone. Clinical safety and efficacy in schizophrenia Psychopharmacol. Bull. 28:1992;213-218.
20. Brady K.T. Weight gain associated with psychotropic drugs. South. Med. J. 82:1989;611-617.
21. Brown A.A., Laughren T.P., Williams B. Differential effects of neuroleptic agents on the pituitary-gonadal axis in men. Arch. Gen Psychiatry. 38:1981;1270-1272.
22. Cabrera R., Mayor P., Fernández-Ruiz J., Calle C. Insulin binding and action on adipocytes from female rats with experimentally induced chronic hyperprolactinemia. Mol. Cell Endocrinol. 58:1988;167-173.
23. Correa N., Opler L.A., Kay S.R., Birmaher B. Amantadine in the treatment of neuroendocrine side effects of neuroleptics. J. Clin. Psychopharmacol. 7:1987;91-95.
24. Creemers L.B., Zelissen P.M.J., van't Verlaat J.W., Koppeschaar H.P.F. Prolactinoma and body weight. A retrospective study Acta Endocrinol. 125:1991;293-396.
25. Demura R., Ono M., Demura H., Shizume K., Oouchi H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17β-estradiol in the human ovary. J. Clin. Endocrinol. Metab. 54:1982;1246-1250.
26. Dorrington J., Gore-Langton R.E. Prolactin inhibits oestrogen synthesis in the ovary. Nature. 290:1981;600-602.
27. Ebeling P.V., Koivisto A. Physiological importance of dehydroepiandrosterone. Lancet. 343:1994;1479-1481.
28. Erle G., Basso M., Federspil G., Sicolo N., Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur. J. Clin. Pharmacol. 11:1977;15-18.
29. Ferreira M.F., Sobrinho L.G., Pires J.S., Silva M.E.S., Santos M.A., Santos M.F.F. Endocrine and psychological evaluation of women with recent weight gain. Psychoneuroendocrinology. 20:1995;53-63.
30. Figlewicz D.P., Schwartz M.W., Seeley R.J., Chavez M., Baskin D.G., Woods S.C., Porte D. Endocrine regulation of food intake and body weight. J. Lab. Clin. Med. 127:1996;328-332.
31. Fitton A., Heel R.C. Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 40:1990;723-747.
32. Ganong, W., ed.: Fisiología Médica, XIVth ed. México: Editorial El Manual Moderno; 1994:445-489.
33. Gerardo-Gettens T., Moore B.J., Stern J.S., Horwitz B.A. Prolactin stimulates food intake in a dose-dependent manner. Am. J. Physiol. 256:1989;R276-R280.
34. Ghadirian M., Chouinard G., Annable I. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 170:1982;463-467.
35. Goodall E., Oxtoby C., Richards R., Watkinson G., Brown D., Silverstone T. A clinical trial on the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. Br. J. Psychiatry. 153:1988;208-213.
36. Gopalaswamy A.K., Morgan R. Too many chronic mentally disabled patients are too fat. Acta Psychiatr. Scand. 72:1985;254-258.
37. Gordon H.I., Groth C. Weight change during and after hospital treatment. Arch. Gen. Psychiatry. 10:1964;187-191.
38. Green A.I., Brown W.A. Prolactin and neuroleptic drugs. Neurol. Clin. 6:1988;213-223.
39. Haffner S.M., Valdez R.A., Stern M.P., Katz M.S. Obesity, body fat distribution and sex hormones in men. Int. J. Obes. Relat. Metab. Disord. 17:1993;643-649.
40. Jakubowicz D.J., Beer N.A., Beer R.M., Nestler J.E. Disparate effects of weight reduction by diet on serum dehydroepiandrosterone-sulfate levels in obese men and women. J. Clin. Endocrinol. Metab. 80:1995;3373-3376.
41. Johnson R.D. Opioid involvement in feeding behaviour and the pathogenesis of certain eating disorders. Med. Hypothesis. 45:1995;491-497.
42. Kandel E.R. Disorders of mood. Depression, mania and anxiety disorders Kandel E.R., Schwartz J.H., Jessell Th.M. Principles of neural science. 1991;869-882 Elsevier Science Publishing Co, New York.
43. Kauppila A., Leinonen P., Vihko R., Ylöstalo P. Metoclopramide-induced hyperprolactinemia impairs ovarian follicle maturation and corpus luteum function in women. J. Clin. Endocrinol. Metab. 54:1982;955-960.
44. Kissebah A.H., Krakover G.R. Regional adiposity and morbidity. Physiol. Rev. 74:1994;761-798.
45. Klett C.J., Caffey E.M. Weight changes during treatment with phenothiazine derivatives. J. Neuropsychiatry. Nov-Dec:1960;102-108.
46. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20:1996;247-252.
47. Leadbetter R., Shutty M., Pavalonis D., Vieweg V., Higgins P., Downs R.N. Clozapine-induced weight gain. Prevalence and clinical relevance Am. J. Psychiatry. 149:1991;68-72.
48. Lee Vance M., Thorner M.O. Prolactin. Hyperprolactinemic syndromes and management Wilson J.D., Foster D.N. Williams textbook of endocrinology. 1992;394-403 W.B. Saunders, Philadelphia, PA.
49. Legros J.J., Demoulin A., Franchimont P. Influence of chlorpromazine on the positive and negative feedback mechanism of oestrogens in man. Psychoneuroendocrinology. 1:1985;185-198.
50. Leibowitz S.F. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. Trends Neurosci. 15:1992;491-497.
51. L'Hermite M., Delogne-Desnoeck J., Michaux-Duchene A., Robyn C. Alteration of feedback mechanism of estrogen on gonadotropin by sulpiride-induced hyperprolactinemia. J. Clin. Endocrinol. Metab. 47:1978;1132-1136.
52. Lin K.C., Kawamura M., Okamura H., Mori T. Inhibition of ovulation, steroidogenesis and collagenolytic activity in rabbits by sulpiride-induced hyperprolactinemia. J. Reprod. Fertil. 83:1988;611-618.
53. Matsuzaki T., Auma K., Irahara M., Yasui T., Aono T. Mechanism of anovulation in hyperprolactinemic amenorrhea determined by pulsatile gonadotropin-releasing hormone injection combined with human chorionic gonadotropin. Fertil. Steril. 62:1994;1143-1149.
54. McNatty K.P., Sawers R.S., McNeilly A.S. A possible role for prolactin in control of steroid secretion by the human Graafian follicle. Nature. 250:1974;653-655.
55. Mendoza S., Scwazemberg A., Zerpa A., Velazquez E., Glueck C.J. Lipids, lipoproteins, and sex hormones in obese men. Its relationship Int. J. Obesity. 10:1986;427-431.
56. Moore B.J., Gerardo-Gettens T., Horwitz B.A., Stern J.S. Hyperprolactinemia stimulates food intake in the female rat. Brain. Res. Bull. 17:1986;563-569.
57. Mroueh A.M., Siler-Khodr T.M. Ovarian refractoriness to gonadotropins in cases of inappropiate lactation. Restoration of ovarian function with bromocryptine J. Clin. Endocrinol. Metab. 43:1976;1398-1401.
58. Murzi E., Baptista T., Hernández L. Hypothalamic sites affecting masticatory neurons in rats. Brain Res. Bull. 26:1991;321-325.
59. Nestler J.E., Barlascini C.O., Clore J.N. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J. Clin. Endocrinol. Metab. 66:1988;57-61.
60. Oades R.D., Schepker R. Serum gonadal steroid hormones in young schizophrenic patients. Psychoneuroendocrinology. 19:1994;373-385.
61. Okonmah A.D., Bradashaw W.G., Couceyro P., Soliman K.F.A. The effect of neuroleptic drugs on serum testosterone level in the male rat. Gen. Pharmacol. 17:1986;235-239.
62. Olefski J.M. Obesity. Isselbacher K.J., Braunwald E., Wilson J.D., Martin J.B., Fauci A.S., Kasper D.L. Harrison's principles of internal medicine. 1992;446-452 McGraw-Hill, New York.
63. Parada M.A., Hernández L., Páez X., Baptista T., Puig de Parada M., Quijada M. Mechanism of the sulpiride-induced obesity. Pharmacol. Biochem. Behav. 33:1989;45-50.
64. Parada M.A., Hernández L., Hoebel B.G. Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats. Pharmacol. Biochem. Behav. 30:1988;917-923.
65. Penn J.V., Martini J., Radka D. Weight gain associated with risperidone. J. Clin. Psychopharmacol. 16:1996;259-260.
66. Rinieris P., Markianos M., Hatzimanolis J., Stefanis C. A psychoendocrine study in male paranoid schizophrenics with delusional ideas of homosexual content. Acta Psychiatr. Scand. 3:1985;309-314.
67. Robinson R.G., McHugh P.R., Folstein M.E. Measurement of appetite disturbances in psychiatric disorders. J. Psychiatr. Res. 12:1975;59-68.
68. Scaglione R., Averna M.R., Dichara M.A., Barbagallo C.M., Mazzola G., Montalto G., Licata G., Notarbatolo A. Thyroid function and release of thyroid-stimulating hormone response and prolactin from the pituitary in obesity. J. Intern. Med. Res. 19:1991;389-394.
69. Simpson G., Pi E.H., Sramek J.J. Adverse effects of antipsychotic agents. Drugs. 21:1981;138-151.
70. Spark R., Wills C., Reilly G., Ransil B. Hyperprolactinemia in males with and without pituitary microadenomas. Lancet. 17:1982;129-131.
71. Stanton J.M. Weight gain associated with neuroleptic medication. A review Schizophr. Bull. 21:1995;463-472.
72. Stedman T., Welham J. The distribution of adipose tissue in female in-patients receiving psychotropic drugs. Br. J. Psychiatry. 162:1993;249-250.
73. Wade G.N., Gray J.M. Gonadal effects on food intake and adiposity. A metabolic hypothesis Physiol. Behav. 22:1979;583-594.
74. Wade G.N., Schneider J.E. Metabolic fuels and reproduction in female mammals. Neuriosci. Biobehav. Rev. 16:1992;235-272.
75. Wang D.Y., De Stavola B.L., Bulbrook R.D., Allen D.S., Kwa H.G., Verstraeten A.A., Moore J.W., Fentiman Y.S., Chaudary M., Hayward J.L., Gravelle L.H. The relationship beetween prolactin levels and risk of breast cancer in premenopausal women. Eur. J. Cancer Clin. Oncol. 23:1987;1541-1548.